Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.

Future oncology (London, England) - 1 Jun 2021

Julia Edith, Salles Gilles

Abstract excerpt

Epigenetic alterations are major drivers of follicular lymphomagenesis, and these alterations are frequently caused by mutations in or upregulation of EZH2, a histone methyltransferase responsible for PRC2-mediated gene repression. EZH2 hyperactivation increases proliferation of B cells and prevents them from exiting the germinal center, favoring lymphomagenesis. The first FDA-approved EZH2 inhibitor is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Enhancer of Zeste Homolog 2 Protein

Share to Lymphoma, Follicular

Share to Maximum Tolerated Dose

Share to Morpholines

Share to Salvage Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 33709777
DOI: 10.2217/fon-2020-1244
PMCID: PMC9892962

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.PMID 33709777Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.Semantic proximity Read ↗

[INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.Semantic proximity Read ↗

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.Semantic proximity Read ↗

Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.Semantic proximity Read ↗

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read ↗

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.Semantic proximity Read ↗

EZH2 mutations are frequent and represent an early event in follicular lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.